Back to search
Schizophrenia Spectrum and Other Psychotic Disorders
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Schizophrenia Spectrum and Other Psychotic Disorders trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Schizophrenia Spectrum and Other Psychotic Disorders trials you may qualify forThis study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMA…
The current study is an open-label, proof-of-concept, pilot trial examining the feasibility, safety, and preliminary efficacy of a 6-week group therapy interven…
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus…
Cannabis use disorder is a frequent comorbidity of schizophrenia, associated with increased symptoms and less adherence to therapy. Validated care has limited e…
The goal of this clinical trial is to learn whether learning and belief updating change in response to the treatment of persecutory delusions, in individuals wi…
This study aims to evaluate the effectiveness of Ashwagandha (Withania somnifera) extract as an adjuvant therapy in patients with schizophrenia who are receivin…
The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophreni…
The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in partic…